A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant

Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte infusions (DLIs) have been reported to control disease, but the...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Richard LeBlanc, Stéphanie Thiant, Rafik Terra, Imran Ahmad, Jean-Sébastien Claveau, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Silvy Lachance, Thomas Kiss, Denis-Claude Roy, Guy Sauvageau, Jean Roy
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	MDPI AG 2024-11-01
Ráidu:	Current Oncology
Fáttát:	allogeneic hematopoietic cell transplant donor lymphocyte infusion minimal measurable disease multiple myeloma
Liŋkkat:	https://www.mdpi.com/1718-7729/31/11/535
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!